Published in Curr Clin Pharmacol on January 01, 2006
Renalase gene polymorphisms in patients with type 2 diabetes, hypertension and stroke. Neuromolecular Med (2011) 1.20
Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients. Hypertens Res (2010) 2.09
Hyperuricemia and cardiovascular disease risk. Expert Rev Cardiovasc Ther (2014) 2.07
Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients. Hypertens Res (2010) 1.54
Irbesartan and hydrochlorothiazide association in the treatment of hypertension. Curr Vasc Pharmacol (2009) 1.40
Prospects for the development of novel anti-hyperlipidemic drugs. Curr Opin Investig Drugs (2006) 1.27
Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium (2006) 1.27
Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials. Expert Opin Biol Ther (2012) 1.18
Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome. Heart Vessels (2007) 1.05
Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. Clin Ther (2003) 1.05
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism (2009) 1.04
Psychosocial factors and metabolic parameters: is there any association in elderly people? The Massa Lombarda Project. Aging Ment Health (2010) 0.96
Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hypertens Res (2007) 0.95
Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients. Diabetes Res Clin Pract (2012) 0.92
Hypertension: management perspectives. Expert Opin Pharmacother (2012) 0.91
The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. Clin Ther (2003) 0.90
A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice. Vasc Health Risk Manag (2007) 0.90
Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load. J Clin Lipidol (2012) 0.89
A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract (2004) 0.89
Clinical perspectives of anti-inflammatory therapy in the elderly: the lipoxigenase (LOX)/cycloxigenase (COX) inhibition concept. Arch Gerontol Geriatr (2004) 0.89
Oral fat load effects on inflammation and endothelial stress markers in healthy subjects. Heart Vessels (2009) 0.88
Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia. Clin Invest Med (2009) 0.88
Cardiometabolic Risks and Obesity in the Young. N Engl J Med (2016) 0.88
Cerebrovascular disease in Italy and Europe: it is necessary to prevent a 'pandemia'. J Cardiovasc Risk (2002) 0.87
Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. Curr Med Res Opin (2009) 0.87
Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients. Diabetes Technol Ther (2012) 0.87
Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies. J Am Soc Hypertens (2013) 0.86
A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus. Clin Ther (2003) 0.85
Metalloproteinase-2 and -9 in diabetic and nondiabetic subjects during acute coronary syndromes. Endothelium (2007) 0.84
Metalloproteinases in diabetics and nondiabetics during acute coronary syndromes and after 3 months. Endothelium (2007) 0.83
Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha. Hypertens Res (2006) 0.83
Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load. Eur J Pharmacol (2010) 0.83
Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients. Endocr J (2010) 0.83
Hypertension and diabetes incidence: confounding factors. Hypertens Res (2011) 0.82
Effects of a standardized oral fat load on vascular remodelling markers in healthy subjects. Microvasc Res (2010) 0.82
Retracted Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study. J Diabetes Complications (2011) 0.82
Modification of vascular and inflammation biomarkers after OGTT in overweight healthy and diabetic subjects. Microvasc Res (2010) 0.81
How to avoid the depression of the adherence to antihypertensive treatment? J Hypertens (2013) 0.81
Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation. Eur J Pharm Sci (2013) 0.81
Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study. Expert Opin Pharmacother (2012) 0.81
Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial. Intern Med (2007) 0.81
Retracted Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients. Pharmacol Res (2013) 0.80
Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial. Curr Med Res Opin (2009) 0.80
Olmesartan/amlodipine combination versus olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients. Clin Exp Hypertens (2012) 0.80
Comparison of orlistat treatment and placebo in obese type 2 diabetic patients. Expert Opin Pharmacother (2010) 0.80
Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. Hypertens Res (2005) 0.80
Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients. Intern Med (2010) 0.79
Zofenopril and ramipril and acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a retrospective analysis in hypertensive patients of the SMILE-4 study. J Hypertens (2013) 0.79
Activity of isoflavones and berberine on vasomotor symptoms and lipid profile in menopausal women. Gynecol Endocrinol (2012) 0.79
Candesartan effect on inflammation in hypertension. Hypertens Res (2010) 0.79
Effects of early treatment with zofenopril in patients with myocardial infarction and metabolic syndrome: the SMILE Study. Vasc Health Risk Manag (2008) 0.78
Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy. Can J Physiol Pharmacol (2013) 0.78
Metabolic syndrome prevalence in Italy. Nutr Metab Cardiovasc Dis (2006) 0.78
ABCA1-dependent serum cholesterol efflux capacity inversely correlates with pulse wave velocity in healthy subjects. J Lipid Res (2012) 0.78
Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients. Fundam Clin Pharmacol (2010) 0.78
Interaction between serum cholesterol levels and the renin-angiotensin system on the new onset of arterial hypertension in subjects with high-normal blood pressure. J Hypertens (2007) 0.78
Effects of insulin therapy with continuous subcutaneous insulin infusion (CSII) in diabetic patients: comparison with multi-daily insulin injections therapy (MDI). Endocr J (2009) 0.78
Modulation of adipokines and vascular remodelling markers during OGTT with acarbose or pioglitazone treatment. Biomed Pharmacother (2009) 0.78
Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients. Metabolism (2010) 0.78
Global cardiovascular disease risk management in italian patients with metabolic syndrome in the clinical practice setting. High Blood Press Cardiovasc Prev (2013) 0.78
Hepatic steatosis index and lipid accumulation product as middle-term predictors of incident metabolic syndrome in a large population sample: data from the Brisighella Heart Study. Intern Emerg Med (2012) 0.78
Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. Pharmacotherapy (2005) 0.77
Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone. Metabolism (2008) 0.77
A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study. Diabetes Technol Ther (2013) 0.77
The role of irbesartan in the treatment of patients with hypertension: a comprehensive and practical review. High Blood Press Cardiovasc Prev (2012) 0.77
Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin. Intern Med (2012) 0.77
Omega-3 polyunsaturated fatty acids: Their potential role in blood pressure prevention and management. Heart Int (2006) 0.77
Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension. J Cardiovasc Pharmacol (2005) 0.77
Synergistic effect of doxazosin and acarbose in improving metabolic control in patients with impaired glucose tolerance. Clin Drug Investig (2006) 0.77
Rationale for the use of a fixed-dose combination in the management of hypertension: efficacy and tolerability of lercanidipine/enalapril. Clin Drug Investig (2010) 0.76
Uricaemia and ejection fraction in elderly heart failure outpatients. Eur J Clin Invest (2014) 0.76
Persistence on treatment and blood pressure control with different first-line antihypertensive treatments: a prospective evaluation. Clin Exp Hypertens (2007) 0.76
Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine. Intern Med (2009) 0.76
Rate of control of LDL cholesterol and incident hypertension requiring antihypertensive treatment in hypercholesterolemic subjects in daily clinical practice. Ann Med (2014) 0.76
Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients. J Pharm Pharm Sci (2010) 0.76
Serum uric acid and markers of low-density lipoprotein oxidation in nonsmoking healthy subjects: data from the Brisighella Heart Study. Pol Arch Med Wewn (2014) 0.76
Retracted Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients. Inflammation (2014) 0.76
Fixed combination of zofenopril plus hydrochlorothiazide in the management of hypertension: a review of available data. Vasc Health Risk Manag (2006) 0.75
Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism (2009) 0.75
Re: The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst (2009) 0.75
Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardio-vascular disease: response to Beishuizen et al. Diabetes Care (2005) 0.75
In response: hyperuricemia as a risk factor for cardiovascular disease. Expert Rev Cardiovasc Ther (2014) 0.75